Millendo Therapeutics (NASDAQ:MLND) Stock Rating Upgraded by ValuEngine

Millendo Therapeutics (NASDAQ:MLND) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday, ValuEngine reports.

A number of other equities analysts have also recently issued reports on MLND. Wedbush began coverage on Millendo Therapeutics in a report on Thursday, July 18th. They set an “outperform” rating and a $24.00 price objective for the company. Zacks Investment Research upgraded Millendo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. CIBC began coverage on Millendo Therapeutics in a report on Tuesday, July 16th. They set an “outperform” rating and a $26.00 price objective for the company. Citigroup began coverage on Millendo Therapeutics in a report on Monday, July 15th. They set an “outperform” rating and a $26.00 price objective for the company. Finally, Oppenheimer began coverage on Millendo Therapeutics in a report on Tuesday, July 16th. They set an “outperform” rating and a $26.00 price objective for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $24.38.

MLND traded down $0.18 during trading hours on Thursday, reaching $8.56. 8,557 shares of the company’s stock traded hands, compared to its average volume of 34,521. The company’s 50-day moving average price is $11.44. Millendo Therapeutics has a 52-week low of $6.77 and a 52-week high of $17.34. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.83 and a quick ratio of 7.83. The firm has a market capitalization of $114.62 million, a price-to-earnings ratio of -0.49 and a beta of 2.64.

Millendo Therapeutics (NASDAQ:MLND) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.08). Sell-side analysts forecast that Millendo Therapeutics will post -3.32 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new stake in shares of Millendo Therapeutics in the 2nd quarter worth $28,000. Geode Capital Management LLC purchased a new stake in shares of Millendo Therapeutics in the 4th quarter worth $113,000. BlackRock Inc. purchased a new stake in shares of Millendo Therapeutics in the 4th quarter worth $203,000. Private Advisors LLC lifted its holdings in shares of Millendo Therapeutics by 9.1% in the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after buying an additional 1,279 shares during the period. Finally, Tibra Equities Europe Ltd purchased a new stake in shares of Millendo Therapeutics in the 1st quarter worth $303,000. Institutional investors and hedge funds own 44.06% of the company’s stock.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Featured Story: What does a bar chart display?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.